Issues that reduce the inflammation (particularly, key inflammatory markers such as pro-inflammatory mediators TNFα, IL-6, IL-1β and CRP) could offer a vital public health tool to reduce the burden of diabetes and associated complications including cardiovascular diseases in the general population. This evidence concerns the gene IL1B and diabetes mellitus.